#South Korea #Seoul #Lunit #Clinical Adoption #Breast Imaging AI

Lunit's Progress in Breast Imaging AI

Lunit, a pioneer in artificial intelligence for cancer diagnostics, has made significant strides in the clinical use of its breast imaging technologies. During the recent Society of Breast Imaging (SBI) Annual Symposium, Lunit proudly announced that it has surpassed 330 screening sites across the Americas, achieving an astonishing milestone of over 1 million annual screening mammograms. This rapid growth not only reflects the increasing adoption of AI in clinical practice but also highlights Lunit's commitment to enhancing patient care through innovative technology.

Comprehensive Breast Cancer Ecosystem

One of the standout implementations comes from Lexington Clinic, the largest physician-owned multi-specialty medical group in Central Kentucky. The clinic has rolled out Lunit's complete AI-powered breast cancer ecosystem, which aims to streamline the entire breast care process from risk assessment to detection. The ecosystem includes tools such as the Lunit INSIGHT® Breast Suite for mammography and digital breast tomosynthesis, Analytics™ for quality optimization, and the Volpara® Scorecard™ for volumetric breast density assessment. Angie Hall, the Breast Center Manager at Lexington Clinic, emphasized that this integration improves team coordination and supports timely decision-making for better patient outcomes.

Real-World Application

The adoption of Lunit's technology extends beyond Lexington Clinic. Over the past year, Lunit has cemented its presence in more than 330 sites across the Americas, reflecting a transformative shift in the industry. Craig Hadfield, CEO of Lunit International, shared insights on this momentum: "Providers are moving beyond pilots into daily clinical use." With more than 1 million screenings taking place annually, the integration of AI in routine practice is evident.

In particular, Radiology Consultants of Iowa (RCI), one of Iowa's largest radiology groups, has incorporated Lunit INSIGHT into its workflows. Dr. Robert J. Dolan, a breast imaging specialist at RCI, expressed his satisfaction with the impact of AI in their daily operations, stating, "After six months of using AI in our workflow, it's become part of how we read." This case illustrates the ongoing benefits clinicians experience from employing AI solutions in their diagnostics.

New FDA-Cleared Technology

Another highlight from the symposium is Lunit's announcement regarding the FDA clearance of its next-generation 3D mammography AI, Version 1.2. This updated version introduces innovative features such as current-prior comparisons, allowing clinicians to assess findings from both current and previously conducted exams. Additionally, it offers multiple operating thresholds tailored to specific clinical environments.

The enhancements brought by this new algorithm reinforce Lunit’s dedication to practical usability. By enabling a seamless integration of AI findings with existing clinical processes, Lunit equips healthcare professionals with tools that expand their diagnostic capabilities while maintaining flexibility in implementation.

Conclusion

Founded in 2013, Lunit is on a mission to transform cancer diagnostics with AI-driven solutions. The company has grown substantially, providing FDA-cleared tools that span the spectrum of cancer care—from risk prediction to targeted treatments. Lunit has established its reputation across over 10,000 sites in more than 65 countries, continuously evolving its datasets to deliver meaningful impacts for patients and healthcare providers.

With its innovative programs and strategic adoption across numerous sites, Lunit is certainly setting the standard in AI-driven breast cancer diagnostics. Learn more about Lunit's mission and advancements in cancer care at their website, lunit.io.